FMT plus ICI in metastatic renal cell carcinoma, Canada
113 gut microbiome samples from adult metastatic renal cell carcinoma patients in London, Canada, in a phase 1 trial combining fecal microbiota transplantation with immune checkpoint inhibitor-based drug therapy. machine-written summary
113 samples · 113 runs · CA · Adult · 2025 · 15.12 Gbp / sample
Checked this project's papers and archive records yourself? Mark it human-verified.
what each source gave
| ✓ Sequence archive | 791 sample values (collection date, country, latitude, location locality, location region, longitude, subject id) |
| ✓ Abstract / description | 113 sample values (health condition detail) |
| ✓ Full text | 226 sample values (health condition, location site) · PMC13099417 |
| ○ Supplementary tables | files read; no table could be matched to the samples |
| – External resources | not covered by the external resources we ingest |
| – User contribution | nothing uploaded yet |
| – Human verified | not yet checked by a person · I checked this project — verify it |
intervention — arms not resolved
Non-antibiotic pharmaceutical given as the study intervention (metformin Faecal microbiota transplantation design single_arm_before_after · population other_cancer · Encapsulated donor FMT plus ICI therapy (ipilimumab/nivolumab or pembrolizumab combos)
“received encapsulated healthy donor FMT (LND101) combined with ipilimumab/nivolumab” — abstract:41606120 (study level; per-sample arms are in the intervention column below)
longitudinal
20 of 20 people sampled more than once (113 samples; median 6, up to 6 per person) · follow-up median 3 mo (max 5 mo) · median interval between samples 21 d (time from collection dates). Schedule stated by the source: “fecal samples at five timepoints (baseline and up to 10 weeks post-FMT)” (time origin: intervention_start).
Each row is one person (20 shown); dots are samples at days since that person's first sample.
Genera, mean relative abundance over 105 profiled gut samples of this project (Sandpiper SingleM profiles, GTDB R232; low-depth and non-metagenome profiles left out).
| field | samples | coverage | R1 | R2 | R3 | R4 |
|---|---|---|---|---|---|---|
| age_category | 113 | 100% | ||||
| country | 113 | 100% | 113 | |||
| health_condition | 113 | 100% | 113 | |||
| subject_id | 113 | 100% | 113 | |||
| collection_date | 113 | 100% | 113 | |||
| detailed_location | 113 | 100% | ||||
| health_condition_detail | 113 | 100% | 113 | |||
| latitude | 113 | 100% | 113 | |||
| location_locality | 113 | 100% | 113 | |||
| location_region | 113 | 100% | 113 | |||
| location_site | 113 | 100% | 113 | |||
| longitude | 113 | 100% | 113 |
- Fecal microbiota transplantation plus immunotherapy in metastatic renal cell carcinoma: the phase 1 PERFORM trial. 2026 PMID 41606120 PMC13099417 own_data
Archive description
The PERFORM trial is a prospective clinical study evaluating the impact of fecal microbiota transplantation (FMT) in combination with immune checkpoint inhibitor-based therapy in patients with metastatic renal cell carcinoma. The trial aims to determine whether FMT can enhance treatment efficacy and reduce toxicity by modulating the gut microbiome.
How this project entered the registry
Classified as human gut / stool shotgun DNA metagenome of adult by sonnet_x2 with confidence 0.68. Assay shotgun_dna.
- host run.scientific_name · “human gut metagenome”
- host study.description · “patients with metastatic renal cell carcinoma”
- body site study.description · “modulating the gut microbiome”
- life stage study.description · “patients with metastatic renal cell carcinoma”
Evidence examples (one per field × route)
| sample | field | value | route | conf. | source | quote |
|---|---|---|---|---|---|---|
| SAMN49940694 | collection_date | 2020-02-13 | R1 | 0.90 | biosample.attribute:collection_date | 2020-02-13 |
| SAMN49940694 | country | CA | R1 | 0.90 | sample.attr.geo_loc_name | Canada:London |
| SAMN49940694 | health_condition | other_cancer | R3 | 0.70 | paper.fulltext.abstract | 20 treatment-naive patients with mRCC received |
| SAMN49940694 | health_condition_detail | metastatic renal cell carcinoma (mRCC) | R4 | 0.50 | paper.abstract | metastatic renal cell carcinoma (mRCC) |
| SAMN49940694 | latitude | 42.9600 | R1 | 0.90 | biosample.attribute:lat_lon | 42.96 N 81.23 W |
| SAMN49940694 | location_locality | London | R1 | 0.85 | biosample.attribute:geo_loc_name | Canada:London |
| SAMN49940694 | location_region | Ontario | R1 | 0.60 | biosample.attribute:lat_lon | 42.96 N 81.23 W |
| SAMN49940694 | location_site | London Health Sciences Centre | R3 | 0.70 | paper.fulltext.methods | conducted at the London Health Sciences Centre |
| SAMN49940694 | longitude | -81.2300 | R1 | 0.90 | biosample.attribute:lat_lon | 42.96 N 81.23 W |
| SAMN49940694 | subject_id | P_1 | R1 | 0.70 | sample.name_rule:biosample.sample_description | P_1_1 |
Sequencing
113 runs over 113 samples · mean 16.75 Gbp per run (median 15.12 Gbp, total 1,892.97 Gbp; 113 runs with a base count) · layout PAIRED 113 · platform ILLUMINA 113 · models Illumina NovaSeq X Plus (113) · 93% of runs with a Sandpiper profile · first public 2025-07-14
Authors (15)
Fernandes R first · Jabbarizadeh B · Rajeh A · Hong MMY · Baines KJ · Ernst S · Winquist E · Ali AS · Penny S · Figueredo R · Parvathy SN · Lenehan JG · Pinto DM · Silverman MS · Maleki Vareki S last
Downloads
PRJNA1290813.csv.gz (4.5 KB) · parquet (75.9 KB) — all 113 samples, every field with route and confidence · PRJNA1290813_determinations.csv.gz (9.0 KB) — 1,130 evidence rows